Clinical Trials Logo

Clinical Trial Summary

This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine kinase inhibitor-naïve NSCLC patients with EGFR-activating mutations who receive a first-line osimertinib orally at a dose of 80mg once daily.


Clinical Trial Description

This open-label, single-arm, non-randomized phase 2 exploratory study has been designed to evaluate the mechanisms of resistance to first-line osimertinib 80mg once daily in NSCLC patients with EGFR-activating mutation who were naïve to chemotherapy as well as EGFR TKIs. Acquired resistance to first-line osimertinib is mediated by heterogeneous mechanisms including MET amplification (15%), secondary EGFR mutation including C797S or S768I (7%), PIK3CA mutation (7%), CDK4/6 amplification (5%), KRAS mutation (3%), BRAF mutation (3%), CCND1-3 amplification (3%), CCNE1 amplification (2%), HER2 amplification (2%), and SPTBN1-ALK fusion (1%) using plasma genotyping of FLAURA study (N=91). Therefore, this study is necessary to evaluate resistance mechanisms of ≥1% to first-line osimertinib in NSCLC patients with EGFR-activating mutations using whole-genomic profiling of tumours at pre-treatment and progression which acquisitions are mandatory. ;


Study Design


Related Conditions & MeSH terms

  • Locally Advanced or Metastatic NSCLC

NCT number NCT03969823
Study type Interventional
Source Seoul National University Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date May 23, 2019
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT03037086 - Asia PDL1 Study Among NSCLC Patients N/A
Recruiting NCT05662670 - A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03274479 - PBF-1129 in Patients With NSCLC Phase 1
Recruiting NCT03502850 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT05990127 - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer Phase 3
Completed NCT04207775 - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed NCT05631678 - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole Phase 1
Not yet recruiting NCT06461156 - A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1
Active, not recruiting NCT04143607 - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC Phase 3
Completed NCT03414814 - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation Phase 2
Completed NCT04360915 - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects Phase 1